SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH

SCS Capital Management LLC acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 9,375 shares of the company’s stock, valued at approximately $914,000.

Other large investors also recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in Dianthus Therapeutics in the 2nd quarter worth about $24,993,000. State of Wyoming purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $300,000. Walleye Capital LLC purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $1,743,000. Handelsbanken Fonder AB bought a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $1,491,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $27,358,000. 47.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Anne Mcgeorge sold 7,750 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director directly owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. The trade was a 86.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 284,306 shares of company stock valued at $29,289,369. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $115.96 on Monday. The company has a 50-day moving average price of $97.47 and a 200-day moving average price of $83.07. Dianthus Therapeutics, Inc. has a 52 week low of $19.84 and a 52 week high of $116.47. The firm has a market capitalization of $6.34 billion, a P/E ratio of -27.94 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reiterated a “strong-buy” rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Finally, Wedbush increased their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.